Andrew Z. Wang, MD, is Associate Professor and Director of Clinical and Translational Research, Department of Radiation Oncology, UNC-Chapel Hill. He is also the co-Director of the Carolina Cancer Nanotechnology T32 training program. Dr. Wang earned his undergraduate degrees from Indiana University and medical degree from the HST program at Harvard Medical School. He completed his radiation oncology training in the Harvard Radiation Oncology Program. Following residency, Dr. Wang joined the UNC faculty in 2009.
Dr. Wang’s research program is focused on the clinical translation of engineering sciences, including Nanomedicine, to oncology. His research spans a wide spectrum of translational research, from preclinical research to early phase clinical trials. His research has been supported by grants from the NIH/NCI and Department of Defense. He is CEO and cofounder of Capio Biosciences, a biotech startup that is translating a nanotechnology-based circulating tumor cell capture assay. Dr. Wang is on the editorial board of several journals, including the Journal of the National Cancer Institute.
